ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Thomas W. LeBlanc, MD, and Eric Roeland, MD, FAAHPM, on Palliative Care for Patients With Hematologic Malignancies

Thomas W. LeBlanc, MD, of Duke University Medical Center, and Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, discuss the use of palliative and hospice care for patients with solid tumors vs hematologic cancers and clinicians’ attitudes (Abstracts e20554 and 9524).

Colorectal Cancer

Chloe Evelyn Atreya, MD, PhD, and Axel Grothey, MD

Chloe Evelyn Atreya, MD, PhD, and Axel Grothey, MD, on Efficacy of Targeted Treatments in BRAF-Mutated Metastatic Colorectal Cancer

Chloe Evelyn Atreya, MD, PhD, of the University of California, San Francisco, talks with Axel Grothey, MD, of the Mayo Clinic, about new data on trametinib, dabrafenib, and panitumumab in patients with the BRAF V600E mutation and vemurafenib plus irinotecan and cetuximab in BRAF-mutated metastatic colorectal cancer (Abstracts 103 and 3511).

Prostate Cancer

Howard M. Sandler, MD, and Christopher Sweeney, MBBS

Howard M. Sandler, MD, and Christopher Sweeney, MBBS, on Results of the RTOG 0521 Trial on Localized, High-Risk Prostate Cancer

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discuss the improvement of overall survival with the use of adjuvant chemotherapy following androgen suppression and radiotherapy (Abstract LBA5002).

Skin Cancer

Jedd Wolchok, MD, PhD

Jedd Wolchok, MD, PhD, Summarizes Results From the CheckMate 067 Trial in Advanced Melanoma

Jedd Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center discusses therapies for treatment-naive patients with advanced melanoma (Abstract LBA1).

Breast Cancer

Julie Gralow, MD and Clifford A. Hudis, MD

Julie Gralow, MD, and Clifford A. Hudis, MD, on Bisphosphonates as Adjuvant Therapy in Primary Breast Cancer

Julie Gralow, MD, of the University of Washington/Seattle Cancer Care Alliance, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss this important SWOG trial and why oral bisphosphonates should be made available in the United States (Abstract 503).

Jul

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Thomas W. LeBlanc, MD, and Eric Roeland, MD, FAAHPM, on Palliative Care for Patients With Hematologic Malignancies

Chloe Evelyn Atreya, MD, PhD, and Axel Grothey, MD, on Efficacy of Targeted Treatments in BRAF-Mutated Metastatic Colorectal Cancer

Howard M. Sandler, MD, and Christopher Sweeney, MBBS, on Results of the RTOG 0521 Trial on Localized, High-Risk Prostate Cancer

Jedd Wolchok, MD, PhD, Summarizes Results From the CheckMate 067 Trial in Advanced Melanoma

Julie Gralow, MD, and Clifford A. Hudis, MD, on Bisphosphonates as Adjuvant Therapy in Primary Breast Cancer

Virtual Sustained Counseling and Tobacco Treatment Improve Quit Rates for Patients With Cancer in Community Settings

Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC

Digital Check-ins May Improve Outcomes in Patients Undergoing Treatment for Advanced Cancer

How Do Surgical Ovarian Cancer Prevention Strategies Compare for Sexual Function?

ENDURANCE Trial in Newly Diagnosed Myeloma No Survival Benefit With Indefinite vs 2 Years of Maintenance Treatment